Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRGILIO: Vismodegib plus radiotherapy in high-risk or locally advanced basal cell carcinoma
2015-004543-40Phase 2Terminated
- Sponsor
- Humanitas Research Hospital
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in basal cell carcinoma (BCC), sponsored by Humanitas Research Hospital. Primary endpoint: Proportion of patients progression-free at 12 months. Started Aug 2018; status: terminated.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2015-004543-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004543-40.